GW Pharmaceuticals PLC- (GWPH) PT Set at $208.00 by Cantor Fitzgerald

GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been assigned a $208.00 price objective by Cantor Fitzgerald in a research note issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 74.19% from the company’s current price.

Several other research firms have also weighed in on GWPH. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research report on Monday, August 7th. Goldman Sachs Group reissued a “neutral” rating and set a $124.00 price target on shares of GW Pharmaceuticals PLC- in a research report on Friday, October 6th. Bank of America dropped their price target on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research report on Tuesday, November 14th. ValuEngine raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC- in a research report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average price target of $144.55.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $119.41 on Monday. GW Pharmaceuticals PLC- has a 52-week low of $92.65 and a 52-week high of $136.95. The company has a quick ratio of 10.26, a current ratio of 10.39 and a debt-to-equity ratio of 0.02.

Hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC increased its position in GW Pharmaceuticals PLC- by 18.0% in the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares during the last quarter. Advisor Group Inc. increased its position in GW Pharmaceuticals PLC- by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $163,000. Woodmont Investment Counsel LLC acquired a new position in GW Pharmaceuticals PLC- in the 2nd quarter worth about $201,000. Finally, Van Hulzen Asset Management LLC acquired a new position in GW Pharmaceuticals PLC- in the 3rd quarter worth about $205,000. 81.85% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/12/06/gw-pharmaceuticals-plc-gwph-pt-set-at-208-00-by-cantor-fitzgerald.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply